{"created":"2023-05-15T09:04:39.428980+00:00","id":5780,"links":{},"metadata":{"_buckets":{"deposit":"e784fa71-478b-46a5-831d-06464293f9c7"},"_deposit":{"created_by":11,"id":"5780","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"5780"},"status":"published"},"_oai":{"id":"oai:hirosaki.repo.nii.ac.jp:00005780","sets":["557:561:976"]},"author_link":["11459","20296","20297","11869","11871","14831","11697","11458"],"control_number":"5780","item_3_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-11-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"38","bibliographicPageStart":"24","bibliographicVolumeNumber":"70","bibliographic_titles":[{"bibliographic_title":"弘前医学","bibliographic_titleLang":"ja"}]}]},"item_3_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Toxic amyloid-beta （Aβ） is known to generate symptoms of Alzheimer’s disease （AD）; however, less is known regarding the neurotoxicity of Aβ at lower concentrations. Moreover, the neuroprotective potential of combination treatment with plant biophenols and existing drugs is not well understood. In this study, we estimated the no-observed adverse effect level （NOAEL） of Aβ 1–42 （Aβ42） against cultured human neuroblastoma SHSY5Y cells, and examined the neuroprotective effect of combination pretreatment with 10 μM carnosic acid, 30 nM rebamipide, 10 μM edaravone, and 10 μM of resveratrol （the “CRER” blend） on weak but toxic Aβ42-treated SH-SY5Y cells. We evaluated the NOAEL of Aβ42 at 500 nM in these cells. Aβ42 at 1–8 μM reduced cell viability; however, the “CRER” blend ameliorated this Aβ42-induced decrease in viability. The “CRER” blend induced the expression of Aβ-degrading enzymes including matrix metalloproteinase-14 （MMP-14） and neprilysin, while also enhancing the expression of the inducible α-secretase TACE （tumor necrosis factor-α-converting enzyme）, sirtuin 1 （SIRT1）, and brain-derived neurotrophic factor（ BDNF）. Collectively, our results indicate that the “CRER” may aid in the prevention of Aβ toxicity by enhancing MMP-14, neprilysin, TACE, SIRT1, and BDNF. Thus, the “CRER” blend may prove to be a promising strategy for the prevention of Aβ-mediated disorders, particularly AD.","subitem_description_type":"Abstract"}]},"item_3_publisher_35":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"弘前大学大学院医学研究科・弘前医学会"}]},"item_3_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00211444","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0439-1721","subitem_source_identifier_type":"PISSN"}]},"item_3_text_4":{"attribute_name":"著者所属","attribute_value_mlt":[{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Neuropathology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"},{"subitem_text_value":"Department of Vascular Biology Institute of Brain Science, Hirosaki University Graduate School of Medicine"}]},"item_3_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshida, Hidemi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hashimoto, Yuko","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukushima, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanji, Kunikazu","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Matsumiya, Tomoh","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Seya, Kazuhiko","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Kawaguchi, Shogo","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Imaizumi, Tadaatsu","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-11-22"}],"displaytype":"detail","filename":"HirosakiMedJ_70(1)_24.pdf","filesize":[{"value":"420.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"HirosakiMedJ_70(1)_24","url":"https://hirosaki.repo.nii.ac.jp/record/5780/files/HirosakiMedJ_70(1)_24.pdf"},"version_id":"1af09306-b64b-4b60-a83b-fb0e018aadb7"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"low-concentration Aβ42","subitem_subject_scheme":"Other"},{"subitem_subject":"cell viability","subitem_subject_scheme":"Other"},{"subitem_subject":"combination treatment","subitem_subject_scheme":"Other"},{"subitem_subject":"SH-SY5Y cells","subitem_subject_scheme":"Other"},{"subitem_subject":"Alzheimer’s disease","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effect of low-concentration amyloid-β 1–42 (Aβ42) on human neuroblastoma SH-SY5Y cell viability: neuroprotective potential of combination use with carnosic acid, rebamipide, edaravone, and resveratrol","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effect of low-concentration amyloid-β 1–42 (Aβ42) on human neuroblastoma SH-SY5Y cell viability: neuroprotective potential of combination use with carnosic acid, rebamipide, edaravone, and resveratrol","subitem_title_language":"en"}]},"item_type_id":"3","owner":"11","path":["976"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-11-22"},"publish_date":"2019-11-22","publish_status":"0","recid":"5780","relation_version_is_last":true,"title":["Effect of low-concentration amyloid-β 1–42 (Aβ42) on human neuroblastoma SH-SY5Y cell viability: neuroprotective potential of combination use with carnosic acid, rebamipide, edaravone, and resveratrol"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-10-25T04:39:43.251166+00:00"}